Suven Life Sciences has completed last patient last visit (LPLV) for its Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease. The company expects to report the top-line data of this study at Alzheimer’s Association International Conference (AAIC) on July 17, 2019 at Los Angeles.
This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of Masupirdine (SUVN-502) in moderate Alzheimer’s Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients. There is an urgent need for treatment options for patients with Alzheimer’s disease (AD) dementia since there are no new drugs discovered or developed since 2003.
Completing this trial represents a significant milestone for the development of company’s lead compound Masupirdine (SUVN-502) in this Phase 2 study in moderate Alzheimer’s disease and moves it a step closer to potentially bringing this new treatment option for people afflicted with moderate Alzheimer’s disease globally.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.